Here's What Analysts Are Forecasting For Indoco Remedies Limited (NSE:INDOCO) After Its First-Quarter Results
Indoco Remedies Limited (NSE:INDOCO) shareholders are probably feeling a little disappointed, since its shares fell 9.0% to ₹217 in the week after its latest first-quarter results. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
Taking into account the latest results, the consensus forecast from Indoco Remedies' four analysts is for revenues of ₹20.3b in 2027. This reflects a notable 8.4% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to soar 375% to ₹2.90. In the lead-up to this report, the analysts had been modelling revenues of ₹20.9b and earnings per share (EPS) of ₹6.60 in 2027. The analysts seem less optimistic after the recent results, reducing their revenue forecasts and making a pretty serious reduction to earnings per share numbers.
Check out our latest analysis for Indoco Remedies
The analysts made no major changes to their price target of ₹264, suggesting the downgrades are not expected to have a long-term impact on Indoco Remedies' valuation. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Indoco Remedies, with the most bullish analyst valuing it at ₹325 and the most bearish at ₹231 per share. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.
Of course, another way to look at these forecasts is to place them into context against the industry itself. It's clear from the latest estimates that Indoco Remedies' rate of growth is expected to accelerate meaningfully, with the forecast 11% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 4.6% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 12% annually. Indoco Remedies is expected to grow at about the same rate as its industry, so it's not clear that we can draw any conclusions from its growth relative to competitors.
The Bottom Line
The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Indoco Remedies. They also downgraded their revenue estimates, although as we saw earlier, forecast growth is only expected to be about the same as the wider industry. The consensus price target held steady at ₹264, with the latest estimates not enough to have an impact on their price targets.
With that in mind, we wouldn't be too quick to come to a conclusion on Indoco Remedies. Long-term earnings power is much more important than next year's profits. At Simply Wall St, we have a full range of analyst estimates for Indoco Remedies going out to 2028, and you can see them free on our platform here..
Even so, be aware that Indoco Remedies is showing 3 warning signs in our investment analysis , and 1 of those is significant...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.